Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 770-778

  Petkau, J ^a   Reingold, S C ^b   Held, U ^c,j   Cutter, G R ^d   Fleming, T R ^e   Hughes, M D ^f   Miller, D H ^g   McFarland, H F ^h   Wolinsky, Jerry S ⁱ  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Scientific and Clinical Review Associates LLC   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^j Sylvia Lawry Centre for Multiple Sclerosis Research   (Germany)

more..

Author keywords

Correlations; Gadolinium enhanced lesions; Magnetic resonance imaging; Multiple sclerosis; Prognosis; Surrogacy

Indexed keywords

CONTRAST MEDIUM;

ARTICLE; CONCURRENT VALIDITY; CONTRAST ENHANCEMENT; DISEASE MARKER; HUMAN; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALIDITY; RELAPSE;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 48349142161     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507088104     Document Type: Article

References (25)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results from a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
2. Johnson, KP, Brooks, BR, Cohen, JA, Ford, CC, Goldstein, J, Lisak, RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results from a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
3. Jacobs, LD, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
4. PRISMS. (Prevention of Relapses and Disability by interferon-beta 1a Subsequently in Multiple Sclerosis) Study Group. Randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: clinical results. Lancet 1998; 352: 1498-1504.
5. Hartung, HP, Gonsette, R, König, N, Kwiecinski, H, Guseo, A, Morrissey, SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002; 360: 2018-2025.
6. Polman, CH, O'Connor, PW, Havrdova, E, Hutchinson, M, Kappos, L, Miller, DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
7. Whitaker, JN, McFarland, HF, Rudge, P, Reingold, SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1: 37-47.
8. McFarland, HF, Barkhof, F, Antel, J, Miller, DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-51.
9. McFarland, HF, Reingold, SC. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler 2005; 11: 669-676.
10. Fleming, TR. Surrogate endpoints and the FDA's accelerated approval process. Health Aff 2005; 24: 67-78.
11. Miller, DH, Grossman, RI, Reingold, SC, McFarland, HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3-24.
12. Miller, DH, Khan, OA, Sheremata, WA, Blumhardt, LD, Rice, GP, Libonati, MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 115-123.
13. Fleming, TR, Demets, RL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
14. Prentice, RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
15. Schach, S, Daumer, M, Neiss, A. Maintaining high quality of statistical evaluations based on the SLCMSR database. Validation procedure of the SLCMSR. Available on line at: http://www.slcmsr.net/download/ publikationen/Validation_Policy.pdf, accessed 6 August 2007.
16. Ioannidis, JPA. Why most published research findings are false. PLoS Med 2005; 2: e124
17. Young, PJ, Lederer, C, Eder, K, Daumer, M, Neiss, A, Polman, CH, et al. Relapses and subsequent worsening of disability in relapsing remitting multiple sclerosis. Neurology 2005; 67: 804-808.
18. Lehmann, EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, Inc., 1975.
19. Schach, S, Scholz, M, Wolinsky, JS, Kappos, L. Pooled historical MRI data as a basis for research in multiple sclerosis - A statistical evaluation. Mult Scler 2007; 13: 509-516.
20. Comi, G, Filippi, M, Wolinsky, JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
21. Molyneux, PD, Barker, GJ, Batkhol, F, Beckmann, K, Dahlke, F, Filippi, M, et al. Clinicl-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001; 57: 2191-2197.
22. Sormani, MP, Bruzzi, P, Beckmann, K, Wagner, K, Miller, DH, Kappos, L, et al. MRI metrics as surrogate endpoints for EDSS progression in SPSM patients treated with IFN beta-1b. Neurology 2003; 60: 1462-1466.
23. Kappos, L, Moeri, D, Radue, EW, Schoetzau, A, Schweikert, K, Barkhof, T, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability of impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 383: 964-969.
24. Agosta, F, Rovaris, M, Pagani, E, Sormoni, MP, Comi, G, Filippi, M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006; 129: 2620-2627.
25. Held, U, Heigenhauser, L, Shang, C, Kappos, L, Polman, C. Predictors of relapse rate in MS clinical trials. Neurology 2005; 65: 1769-1773.